Genomics of Primary and Metastatic Cutaneous Melanoma: A Systematic Review and Meta-Analysis
American Journal of Clinical Dermatology · 2026-09 · 27 (5) · 887-907
DOI: 10.1007/s40257-026-01031-4 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift American Journal of Clinical Dermatology, online erschienen am 14.05.2026. Verfasst von Manh Duc Hoang und 5 weiteren Autor:innen. Beteiligte Einrichtung: National Cancer Hospital, Cancer Research and Clinical Trials Center, Hanoi, Vietnam. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
BACKGROUND: Melanoma is an aggressive skin cancer with limited durable responses despite therapeutic advances. Comprehensive characterization of genomic alterations may improve understanding of disease progression and inform therapeutic strategies. OBJECTIVE: We aimed to characterize genomic alterations in cutaneous melanoma and compare mutation prevalences between primary and metastatic tumors to improve therapeutic strategies. METHODS: We conducted a systematic review and meta-analysis of genomic data from primary and metastatic cutaneous melanomas to assess the prevalence of gene mutations and copy number alterations. Relevant studies were identified in MEDLINE and Embase up to October 2024 using the search algorithm ((Mutation) OR "Genomics"[Mesh]) AND ("Melanoma"[Mesh]). Data were synthesized using random-effects meta-analyses to estimate the pooled prevalence of gene mutations and copy number variations, with heterogeneity assessed using I2 statistics. This study was reported in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. RESULTS: Ninety-nine publications were included, encompassing 10,386 primary cutaneous melanoma samples and 4273 metastatic samples. The most frequently mutated genes in both settings were BRAF, TERT, TP53, NRAS, and NF1. The prevalence of BRAF, NRAS, TERT, CDKN2A, and PTEN mutations was significantly higher in metastatic lesions. NRAS mutations were more common in central nervous system metastases than in other metastatic sites. In contrast, KIT mutations were more common in primary tumors. Acral melanoma exhibited a distinct molecular profile, with an overall lower mutation prevalence, particularly involving BRAF. Chromosomal losses at 9p21.3 and 9p21 were commonly observed in both primary and metastatic tumors, with higher prevalence in primary tumors. CONCLUSIONS: Our findings highlight distinct genomic differences between primary and metastatic melanoma, underscoring the value of metastatic tumor biopsies in informing molecularly guided treatment decisions. Cutaneous melanoma is the most serious type of skin cancer. The number of cases is rising, especially among people with fair skin in developed countries, with over 330,000 new cases and more than 58,000 deaths worldwide each year.New treatments have improved survival for many patients. Immunotherapy, which helps the immune system fight cancer, and targeted therapy, drugs that block specific genetic changes in cancer cells, have helped people with advanced melanoma live longer. However, melanoma can eventually stop responding to these therapies, so new treatment targets are urgently needed.In this study, we reviewed data from 99 published studies, including over 10,300 primary melanoma cases and 4200 metastatic cases, to find out how often genetic changes occur and to compare primary tumors with metastatic tumors.We found that several genes were commonly altered, including BRAF, TERT, TP53, NRAS, and NF1, with BRAF being the most frequent, occurring in nearly 40% of cases. Some changes, including BRAF, NRAS, TERT, CDKN2A, and PTEN, were more common in metastatic melanoma. NRAS changes were especially frequent in tumors that spread to the brain. Loss of a chromosome region called 9p21 was also seen in both primary and metastatic tumors, but more often in primary tumors.These findings show clear genetic differences between primary and metastatic melanoma. Testing metastatic tumor samples may provide more accurate information to help guide treatment decisions for patients with advanced disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- National Cancer Hospital, Cancer Research and Clinical Trials Center, Hanoi, Vietnam.
- SynKoMIC Research Unit, Université Sorbonne Paris Nord, Villetaneuse, France.
- Hanoi Medical University, Hanoi, Vietnam.
- Université Paris Cité, INSERM U976 HIPI, Paris, France.
- APHP, Dermatolo-Oncology, Hôpital Saint Louis, Paris, France.
- National Cancer Hospital, Cancer Research and Clinical Trials Center, Hanoi, Vietnam. guilhem.bousquet@aphp.fr.
Zitieren
APA
Hoang, M. D., Bui, T. O., Dao, V. T., Le, V. Q., Lebbé, C., & Bousquet, G. (2026). Genomics of Primary and Metastatic Cutaneous Melanoma: A Systematic Review and Meta-Analysis. American Journal of Clinical Dermatology, 27(5), 887-907. https://doi.org/10.1007/s40257-026-01031-4
Vancouver
Hoang MD, Bui TO, Dao VT, Le VQ, Lebbé C, Bousquet G. Genomics of Primary and Metastatic Cutaneous Melanoma: A Systematic Review and Meta-Analysis. American Journal of Clinical Dermatology. 2026;27(5):887-907. doi:10.1007/s40257-026-01031-4
BibTeX
@article{Hoang2026,
author = {Hoang, Manh Duc and Bui, Thi Oanh and Dao, Van Tu and Le, Van Quang and Lebbé, Céleste and Bousquet, Guilhem},
title = {Genomics of Primary and Metastatic Cutaneous Melanoma: A Systematic Review and Meta-Analysis},
journal = {American Journal of Clinical Dermatology},
year = {2026},
volume = {27},
number = {5},
pages = {887--907},
doi = {10.1007/s40257-026-01031-4}
}
EUVIMED